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ABSTRACT
Vancomycin-resistant enterococci (VRE) have become a major nosocomial threat. Enterococcus faecium is of special concern, as
it can easily acquire new antibiotic resistances and is an excellent colonizer of the human intestinal tract. Several clinical studies
have explored the potential use of beneficial bacteria to weed out opportunistic pathogens. Specifically, the widely studied Lacto-
bacillus rhamnosus strain GG has been applied successfully in the context of VRE infections. Here, we provide new insight into
the molecular mechanism underlying the effects of this model probiotic on VRE decolonization. Both clinical VRE isolates and
L. rhamnosusGG express pili on their cell walls, which are the key modulators of their highly efficient colonization of the intesti-
nal mucosa. We found that one of the VRE pilus clusters shares considerable sequence similarity with the SpaCBA-SrtC1 pilus
cluster of L. rhamnosusGG. Remarkable immunological and functional similarities were discovered between the mucus-binding
pili of L. rhamnosus GG and those of the clinical E. faecium strain E1165, which was characterized at the genome level. More-
over, E. faecium strain E1165 bound efficiently to mucus, which may be prevented by the presence of the mucus-binding SpaC
protein or antibodies against L. rhamnosusGG or SpaC. These results present experimental support for a novel probiotic mech-
anism, in which the mucus-binding pili of L. rhamnosusGG prevent the binding of a potential pathogen to the host. Hence, we
provide a molecular basis for the further exploitation of L. rhamnosusGG and its pilins for prophylaxis and treatment of VRE
infections.
IMPORTANCE
Concern about vancomycin-resistant Enterococcus faecium causing nosocomial infections is rising globally. The arsenal of anti-
biotic strategies to treat these infections is nearly exhausted, and hence, new treatment strategies are urgently needed. Here, we
provide molecular evidence to underpin reports of the successful clinical application of Lactobacillus rhamnosusGG in VRE de-
colonization strategies. Our results provide support for a newmolecular mechanism, in which probiotics can perform competi-
tive exclusion and possibly immune interaction. Moreover, we spur further exploration of the potential of intact L. rhamnosus
GG and purified SpaC pilin as prophylactic and curative agents of the VRE carrier state.
For years, enterococci were viewed as harmless endogenousmembers of the human microbiota (1), with some strains even
being used as probiotics (2). However, over 25 years ago, concerns
started to grow as vancomycin-resistant enterococci (VRE) devel-
oped into a rapidly spreading nosocomial threat (3–6).
Presently, the prevalence of nosocomial infections caused by
VRE is escalating globally (4, 5, 7, 8). These Enterococcus species
are successful nosocomial agents since they are excellent coloniz-
ers, show striking genome plasticity, and persist for long periods of
time in the intestinal tract, on medical devices, or on household
appliances (4). Especially in immunosuppressed patients, VRE
rapidly colonize the small intestine, cecum, and colon, thus out-
competing healthy gut microbiota. The virulence factors of VRE
have yet to be fully unraveled, but the high colonization capacity
of VRE is considered to be the main factor contributing to its
pathogenicity (7, 9, 10). Moreover, VRE are remarkably efficient
at acquiring antimicrobial resistances, further enhancing their
persistence and colonization potential. The multiple antibiotic re-
sistances of these enterococci are of special concern, as treatment
of these infections becomes increasingly challenging. This further
stimulates gut colonization by VRE, as the healthy gut microbiota
is detrimentally affected during antibiotic treatment courses. The
rapid acquisition of vancomycin resistance genes (van genes) is
particularly worrisome (7, 8, 11). Vancomycin is the go-to antibi-
otic used to treat infections of Gram-positive bacteria that are
known to be antibiotic resistant, and it is featured on the list of
essential medicines of the WHO (12).
While initially the highly pathogenic Enterococcus faecalis was
viewed as the major threat, it has been surpassed slowly but surely
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by its less pathogenic relative Enterococcus faecium. This trend is
especially alarming, as E. faecium is highly efficient in the acquisi-
tion and accumulation of antibiotic resistance genes (4, 8, 10, 11).
To win the arms race between this bacterium and the search for
new antibiotics, the need to evaluate alternative strategies is high.
Several experts point out that the high colonization capability ofE.
faecium is the key feature to tackle (7, 9, 13). A plethora of strate-
gies has been proposed, including “using the good to weed out the
bad,” i.e., the administration of probiotics as a decolonization
strategy (13, 14). In this respect, the capacity of Lactobacillus
rhamnosus GG to eradicate VRE carriage has been evaluated in
multiple clinical trials (13, 15–17). Administration of yogurt con-
taining L. rhamnosusGG to renal patients resulted in the clearance
of VRE in the treatment group, with most patients remaining VRE
negative for at least 4 weeks after trial completion (16). In a Polish
trial focusing on VRE-colonized children, L. rhamnosus GG treat-
ment resulted in the temporary elimination of the VRE carrier
state (17). In another clinical trial, focusing on adults with comor-
bidities, L. rhamnosus GG seemed to have no effect on VRE coloni-
zation, which may be due to the comorbidities presented by the pa-
tients and the short administration period (15). Based on these
clinical trails and the revision of new case studies, Cheng and cowork-
ers have suggested that a combination of antimicrobial therapy (in-
cluding patient isolation and disinfection) and probiotic treatment
with L. rhamnosus GG may hold the key for successful sustained
decolonization of gastrointestinal carriage of VRE (13).
In this work, we provide new molecular insight into the mecha-
nism underlying the role of L. rhamnosus GG in consolidation of
VRE decolonization. Various Gram-positive species, including some
lactobacilli, harbor pilus gene clusters that may be expressed as pro-
teinaceous cell wall appendages, which contribute to their adhesion
and signaling capacities (18–20).L. rhamnosusGG produces sortase-
dependent pili that are decorated with the mucus-binding protein
SpaC, to which its colonization capacities are attributed (21–24). Ear-
lier work reported the enrichment of intact pilus gene clusters (con-
taining LPXTG-type pilin proteins and a cognate class C-type
sortase) in hospital-acquired E. faecium isolates (25, 26). We deter-
mined the complete genome sequence of the clinical E. faecium
strain E1165. Comparison of pilin gene cluster 3 (PGC-3) of E.
faecium E1165 and the SpaCBA pili of L. rhamnosus GG revealed a
high level of sequence similarity between the two pilus gene clus-
ters. Hence, we tested the capacity of the L. rhamnosusGG pili, and
in particular the adhesive SpaC subunit, as well as antibodies
raised against these components to interfere withE. faeciumE1165
and its mucus interaction. Our findings not only demonstrate the
existence of a novel immunogenic probiotic mechanism in the widely
exploited intestinal isolate L. rhamnosus GG, but they also hold great
promise for the development of prophylactic treatments.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Lactobacillus rhamnosus GG
and its pilus-deficient derivative strain PB12 were grown at 37°C in MRS
broth (Difco) in nonshaking conditions. Enterococcus faecium was grown
stationary in brain heart infusion (BHI) broth (Difco) at 37°C. The three
strains were grown in semianaerobic conditions, i.e., stationary growth
and minimal oxygen. Escherichia coli was cultured aerobically at 37°C in
LB medium under shaking conditions.
Genome sequencing. The genomic DNA of E. faecium isolate E1165
was extracted using the Wizard genomic DNA purification kit (Promega)
per the manufacturer’s recommendations. Genomic DNA sequencing of
E. faecium isolate E1165 was performed using the Pacific Biosciences se-
quencing technology of the DNA Sequencing and Genomics Laboratory
of the Institute of Biotechnology, University of Helsinki. In short, the
PacBio library kit was used to construct a library with size targeted to 10
kb. Two single-molecule real-time (SMRT) cells were run on a PacBio RS
II system using P6/C4 chemistry and 240 min of video time. A total of
78,536 reads (N50 length, 13,229 bp) were assembled using the HGAP.3
implemented in the SMRT analysis system (smrtanalysis_2.0.3; Pacific
Biosciences). Apart from the complete chromosome (2,766,743 bp), a
megaplasmid of 192,533 bp and one smaller plasmid of 32,402 bp were
obtained with mean coverages of 190, 210, and 260, respectively.
Additionally, a circular phage genome (38,742 bp, 50) was found. Using
the RAST server (27), 3,024 open reading frames (ORFs) were predicted
in the E. faecium E1165 genome and phage.
Production of antiserum. Serum samples were obtained from four
patients that had E. faecium bacteremia. Samples were obtained during
normal blood withdrawal and were approved by the medical ethical com-
mittee of the University Medical Center of Utrecht. PilB-specific rabbit
immune serum and SpaC antiserum were produced as described earlier
(25, 28). Antiserum against L. rhamnosus GG was produced as described
recently (29). Controls with preimmune sera of PilB, SpaC, and L. rham-
nosus GG were performed earlier and rendered negative results (25) (re-
sults not shown).
Production of recombinant SpaC protein in E. coli. The coding se-
quence of spaC (LGG_00444), excluding the C-terminal cell wall sorting
signal and the N-terminal signal peptide, was PCR amplified from a
codon-optimized spaCBA gene cluster (primers BG3764 ttcTCATGActg
ataacattcgcccaacc and BG3765 ttcGCGGCCGCcggcaaaattgcaagtgg). The
purified PCR product was digested with BspHI and NotI (marked in cap-
ital letters in the primer sequences) and cloned into the pWUR533 vector,
resulting in pWUR533_SpaC. This vector is a derivative of the pET52-1b
vector in which the C-terminal thrombin protease site was replaced by an
HRV 3C protease site and a Strep-tag II instead of a His tag. One percent
of an overnight culture of E. coli BL21(DE3)/pSJS1244, in which the
pWUR533_SpaC vector was introduced, was grown in LB medium with
ampicillin (100 g/ml) and spectinomycin (50 g/ml). After 3 h of incu-
bation at 37°C, protein production was induced by isopropyl--D-thio-
galactopyranoside (IPTG) (1 mM). Three hours later, cells were harvested
by centrifugation. Purification of the recombinant SpaC protein was per-
formed in accordance with the Strep-Tactin resin manufacturer’s recom-
mendations (IBA). The Strep-tag was removed using the HRV 3C pro-
tease (EMD Millipore) following the protocol of the manufacturer. The
tag and protease were subsequently removed using a Vivaspin 20 centrif-
ugal concentrator (Sartorius).
Mucus-binding assays. Assessment of the binding of strains to mucus
was performed as described earlier (30, 31). Bacterial cells were grown over-
night in an appropriate medium supplemented with 1 mCi/ml [3H]thymi-
dine (Perkin-Elmer Life Sciences). Bacteria (optical density at 600 nm
[OD600], 0.25) were applied to a Nunc MaxiSorp plate coated with 0.5 mg/ml
type II porcine mucus (Sigma-Aldrich, MO, USA). Optionally, 1/100 dilu-
tions of antisera against total L. rhamnosus GG cells (raised as described in
reference 29) and the SpaC subunit of the pili of L. rhamnosus GG (28) were
added immediately to allow competition. Recombinant SpaC was added in a
final concentration of 4.6 ng/l. Bacteria were allowed to bind to mucus for
1 h at 37°C. After this, the plate was washed a few times with phosphate-
buffered saline (PBS) prior to cell lysis (1 h at 60°C). The 3H measurement
protocol has been extensively described previously (31).
Immunogold electronmicroscopy. Immunogold electron microscopy
was performed as described earlier with minor modifications (21, 23, 25). In
the first labeling step, the grids were incubated with rabbit SpaC antiserum
diluted 1:120 in blocking solution or PilB antiserum diluted 1:5, followed by
washing with 0.1% bovine serum albumin (BSA) in PBS. In the case of dou-
ble-labeling experiments, a second labeling was performed using antisera in
similar concentrations as described earlier. The grids were analyzed using a
JEM-1400 transmission electron microscope (JEOL).
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Data analysis. Data analysis was performed using GraphPad Prism 6.
Significant differences between two values were calculated using paired t
tests, and the significance level was set at a P value of0.05.
Accession number(s). The complete circular genome, the two plas-
mid sequences, and phage sequences were deposited in the European
Nucleotide Archive (ENA) under project ID PRJEB12401 and genome
accession numbers LN999987 to LN999990.
RESULTS
Homology of pili of hospital-associated VRE and Lactobacillus
rhamnosus GG. To grasp the molecular basis of the decoloniza-
tion effect of L. rhamnosus GG on VRE shown in clinical trials
(13), we focused on their surface adhesion molecules. Specifically,
SpaCBA pili ofL. rhamnosusGG are described as primary adhesive
molecules, which explains the mucus adhesion capacity of this
probiotic (21, 22, 24, 31, 32). In addition, enterococci are known
to produce pili that are important in colonization and adhesion to
(a)biotic surfaces (19, 33, 34). The E. faecium type strain TX16
harbors four distinct pilin gene clusters (PGCs) (35), and hospital
isolates of E. faecium are enriched in PGCs (25, 26).
A homology search exploring potential similarity between the
PGCs of L. rhamnosus GG and E. faecium resulted in a striking
similarity (50%) between the SpaCBA-SrtC1 pilus cluster of L.
rhamnosus GG and the PGC-3 cluster of E. faecium. Scanning the
organization of the PGC-3 gene cluster, harboring the PilB-type
pili (25), revealed a similar sequence and organization as the well-
studied SpaCBA pili of L. rhamnosus GG (21, 22, 24, 36) (Fig. 1).
Closer investigation revealed that the SpaC pilin of L. rhamnosus
GG was 33% identical to the tip pilin protein sequence of the E.
faecium TX16 strain (ORF 2571). This similarity rose up to 49%
when taking the amount of positive matches into account. Over-
all, mapping of the SpaC protein sequence to the E. faecium tax-
onomy identification number (taxid) 1352 revealed that in some
strains, the sequence similarity even surpasses 50% (54% and up
to 65% when considering positive matches) (data not shown).
As a case study for hospital acquired VRE, we focused on the
clinically relevant E. faecium strain E1165, originally isolated from
the wound/soft tissue of a hospitalized patient in 1997 (Genoa,
Italy). Expression of the PGC-3 cluster-encoded PilB-type pili in
E. faecium E1165 was already confirmed previously (25). We used
PacBio RS II long-read sequencing technology to determine the
complete genome sequence of strain E1165, which was deposited
in the European Nucleotide Archive (ENA) under project ID
PRJEB12401 and genome accession numbers LN999987 to
LN999990. Detailed analysis of the E1165 genome revealed that
the 2.766-Mb large genome contains three pilin gene clusters, as
well as an additional pilin gene cluster (PilA gene cluster or
PGC-1) located on a megaplasmid of 192.533 kb (37). The four
gene clusters of E1165 are highly (99%) homologous to the
PGCs of the TX16 type strain (data not shown).
Cross-reactivity of antibodies reveals structural and immu-
nological similarities between pili of E. faecium E1165 and L.
rhamnosus GG. To explore the functional relationship between
the L. rhamnosus GG and E. faecium E1165 pili, we performed
immunogold electron microscopy experiments using antibodies
directed against the pilin subunits of each of these strains. Inter-
estingly, antibodies raised against the SpaC subunit of the SpaCBA
pili ofL. rhamnosusGG specifically bound to the pili on the surface
of E1165 (in immunogold labeling experiments) (Fig. 2). These
results suggest that the sequence similarity between the SpaC pilin
of L. rhamnosus GG and the tip pilin of E1165 may be indicative of
a stronger, antigenic relation between the two pilus clusters. Next,
we sought to investigate the nature of the targeted pili by setting up
a double-labeling experiment that included both antibodies raised
against the SpaC pilin of L. rhamnosus GG and PilB of E1165.
Immunogold electron microscopy revealed that PilB is located in
the same E. faecium pilus fiber that also reacts with gold-labeled
antibodies against SpaC. This colocalization of both antibodies on
FIG 1 Sequence homology of pilus gene clusters of Enterococcus faecium E1165 and Lactobacillus rhamnosus GG. Pilus gene clusters of both E. faecium E1165
(99% similar to the TX16 type strain) (25) and L. rhamnosus GG (23) are shown. Overall, the clusters have a similar buildup and share a high sequence
homology (50% similarity), and both harbor a sortase (black), a tip adhesin (white), and two pilins (gray). The tip pilins of both strains ORF 2571 (TX16 and
E1165) and spaC share 33% identity (49% positive matches). Arrow sizes reflect gene sizes.
FIG 2 L. rhamnosus GG SpaC pilin-specific antibodies bind to E1165 pili.
Immunogold labeling microscopy using SpaC antibodies shows binding of
these L. rhamnosus GG major pilin-specific antibodies to the pili of E. faecium
E1165 cells. Representative experimental results are shown (scale bar, 200 nm).
Tytgat et al.
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the pili of E1165 confirms them being PilB-type pili expressed by
PGC-3 (Fig. 3). This cross-reactivity of L. rhamnosus GG and
E1165 pilin-specific antibodies illustrates that these pili are not
only related on a genetic level but also on an antigenic level. The
sequence homology seems to result in structurally related pilins,
thus explaining the cross-reactivity of the antibodies.
Next, we set out to relate these results to the clinical effect of L.
rhamnosus GG administration on VRE colonization (13, 16, 17).
Serum samples of patients with VRE bacteremia and healthy persons
were isolated. Immunogold electron microscopy revealed that the
serum samples of all VRE-colonized patients bound to L. rhamnosus
GG, with the highest binding density on the SpaCBA pili (Fig. 4A and
B). As expected, this interaction was absent when testing serum sam-
ples from healthy patients (Fig. 4C). These results suggest that the pili
of both species are indeed related and that their sequence and anti-
genic homology might underpin the clinical results.
L. rhamnosus GG-derived molecules effectively displace E.
faecium from mucus. Ultimately, we investigated whether the se-
quence and antigenic homology between the pili ofL. rhamnosusGG
and E1165 could be exploited in the decolonization of E. faecium as
suggested by clinical trials (13). As pili are known to be key in the
colonization and adhesion of microbes in the human intestinal tract
by binding to human mucus (38, 39), we investigated the mucus-
binding capacities of L. rhamnosus GG and E. faecium E1165 in the
presence and absence of specific antibodies against the former.
In accordance with earlier results, L. rhamnosus GG strongly
bound to mucus (21, 24, 31). This interaction may be attributed
largely to the presence of the SpaCBA pili, as a pilus-deficient
derivative of L. rhamnosus GG, strain PB12, can only minimally
adhere to mucus (31) (P 0.0001) (Fig. 5). E. faecium E1165 was
also found to interact strongly with the mucus (Fig. 5). Interaction
levels were significantly higher (P  0.05) for strain E1165 than
those for L. rhamnosus GG, which may be indicative of a stronger
binding of E1165 to mucus or the presence of more pili per cell. In
view of the similarity between the pili of E. faecium and those of L.
rhamnosus GG, we hypothesized that the E. faecium E1165 pili are
the principal actors of its strong mucus adhesion. Hence, we
sought to study the capacity of antibodies raised against L. rham-
nosus GG and its SpaC pilin to affect E. faecium E1165 mucosal
adhesion. Antibodies that were raised against the SpaC adhesive
pilin effectively interacted with the binding of E1165 to mucus
(Fig. 5). In addition, antibodies raised against intact L. rhamnosus
GG cells could significantly interfere with E. faecium E1165 mucus
binding (P  0.0001) (Fig. 5). The effectiveness of the anti-L.
rhamnosus GG antibodies can most probably be explained by the
presence of reactive anti-SpaC antibodies in the polyclonal serum.
Finally, the SpaC pilin produced and purified from E. coli was
found to significantly reduce (P 0.05) the mucus binding of E.
faecium E1165 (and L. rhamnosus GG) (data not shown) (Fig. 5).
In conclusion, these data indicate that L. rhamnosus GG and E.
faecium E1165 pili compete for the same binding sites on mucus.
FIG 3 L. rhamnosus GG SpaC pilin antibodies colocalize with E. faecium PilB pilin antibodies on E1165 pili. E. faecium E1165 cells were incubated with gold
particles either labeled with PilB antibodies (10-nm particles, black arrows in C) or SpaC antibodies (15-nm particles, white arrows in C). Both labels colocalize
on the pili of E1165, indicating their specificity for the PilB-type pili of E. faecium E1165 expressed by PGC-3. (A) Complete E1165 cells (scale bar, 200 nm). (B
and C) Zoomed-in image of the labeled pili (scale bars, respectively, 100 nm and 50 nm). Results of a representative experiment are shown.
FIG 4 Serum from VRE-colonized patients interacts with L. rhamnosus GG pili, as shown by immunogold labeling microscopy of L. rhamnosus GG in patient
serum samples. (A and B) Serum samples from two different patients infected with VRE. (C) Serum from a healthy patient (scale bar, 200 nm). Pictures of
representative experiments are shown.
Mechanism for Eradicating VRE by L. rhamnosus GG
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DISCUSSION
Infections with vancomycin-resistant E. faecium or VRE have be-
come a major nosocomial threat (4). Effective treatment can no
longer rely on the application of antibiotics, as these bacteria are
extremely efficient at accumulating antibiotic resistance genes in
their genomes (11). This is related to the notion that multidrug-
resistant enterococci lack the clustered regularly interspaced short
palindromic repeat (CRISPR)-Cas system, a natural defense sys-
tem (40). The full genome sequence of E. faecium strain E1165 did
not reveal the presence of any CRISPR-Cas-related genes, reflect-
ing its capacity to rapidly acquire antibiotic resistance genes
(CRISPRdb screening [41]; results not shown).
New strategies to tackle VRE are currently being explored, in-
cluding the implementation of probiotics such as L. rhamnosus
GG (13). Several clinical trials have explored the efficacy of L.
rhamnosus GG to interfere with VRE colonization in different
setups (13, 15–17). Various studies, focusing on renal patients
(16), children (17), and patients suffering from endocarditis and
liver problems (13), illustrated the efficacy of L. rhamnosus GG
administration in sustained colonization resistance against VRE.
The effect of L. rhamnosus GG on VRE decolonization has been
consistently demonstrated by all successful clinical trials. As the
SpaCBA pili of L. rhamnosus GG are the main actors of its high
adhesive phenotype, we sought to investigate the potential role of
these molecules in its beneficial clinical effect against VRE coloni-
zation. Intriguingly, the SpaCBA pili of L. rhamnosus GG show a
striking sequence homology to the PilB-type pili of enterococci
encoded by the PGC-3 cluster. This is of special importance, as
pilus gene clusters are enriched in pathogenic VRE strains (25, 26).
A clinical isolate, E. faecium E1165, was earlier shown to express
these PilB-type pili (25). The complete genome analysis of E1165
confirmed the presence of an intact PGC-3 cluster in its genome,
and this strain was further used throughout the study.
Immunogold electron microscopy experiments revealed that
the pili of L. rhamnosus GG and E. faecium E1165 not only share a
high sequence homology but are also immunologically related. In
particular, antibodies raised against the SpaC pilin ofL. rhamnosus
GG specifically interacted with the pili of E. faecium E1165. Fur-
ther double-labeling experiments using specific antibodies against
SpaC and PilB resulted in their colocalization on the PilB pili of E.
faecium E1165. These results underline the antigenic relation be-
tween the two pilus clusters. Furthermore, we can relate these
results to the clinical trials (13), as patient serum samples from
VRE carriers interacted with L. rhamnosus GG cells and, in partic-
ular, with the surface-exposed and mucus-binding pili.
As colonization of the human intestine is most likely to rely
predominantly on the interaction between bacteria, and more
particularly on their adhesive pili, and the intestinal mucus (38,
39), the effect of L. rhamnosus GG on VRE mucus-binding was
explored. These experiments resulted in the conclusion that anti-
bodies raised against L. rhamnosus GG and its SpaC pilin inter-
fered with the mucus-binding capacity of E. faecium E1165. The
importance of the pili in this effect was further underpinned by the
capacity of the purified SpaC pilin to drastically reduce the bind-
ing of E. faecium E1165 to mucus.
Based on our results, we suggest a novel probiotic mechanism in
which probiotics are not only applied to perform interspecies com-
petitive exclusion but are also inducers of cross-immunity against
potential pathogens. The effect of L. rhamnosus GG on the decoloni-
zation of VRE implies a specific mechanistic effect of this probiotic on
the gut community, which has not been reported to date.
In this work, we have successfully elucidated a molecular
mechanism underlying the successful application of L. rhamnosus
GG to eradicate E. faecium in several clinical trials and spur the
further implementation of L. rhamnosus GG in VRE treatment
(13). L. rhamnosus GG and its purified SpaC pilin can play impor-
tant roles in the improvement of VRE treatment, the consolida-
tion of its decolonization, and the development of effective strat-
egies to tackle the (asymptomatic) carrier state of VRE. Our results
shed light on a unique mechanism to specifically target VRE with-
out harming commensal microbiota.
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